Status: Recruiting
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
This is a first-in-human, multi-part clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), food effect, and drug-drug interaction (DDI) potential of GV-100 following oral administration in healthy participants. The study is divided into four parts: Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Food Effect (FE), and Drug-Drug Interaction (DDI).
Participants needed: 80
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Gilva Therapeutics Inc.Updated: Aug 26, 2026Locations: 1
Eligibility criteria
Male or female participants, aged more than or equal 18 to less than or equal to... [+3]
Any clinically significant abnormal finding on physical examination, as determin... [+23]